A45 INFLIXIMAB IN COMBINATION WITH AN IMMUNOMODULATOR IS ASSOCIATED WITH AN ATTENUATED ANTIBODY RESPONSE TO BNT162B2 SARS-COV-2 VACCINE IN PEDIATRIC INFLAMMATORY BOWEL DISEASE PATIENTS

BACKGROUND: Adult data have shown that Infliximab (IFX) impairs the antibody response to a single dose of the mRNA-BNT162b2 SARS-CoV-2 vaccine in patients with inflammatory bowel disease (IBD). The true impact of IFX on SARS-CoV-2 vaccine efficacy in pediatric IBD (PIBD) patients is unknown. AIMS: T...

Descripción completa

Detalles Bibliográficos
Autores principales: Lawrence, S, Shire, Z, Reicherz, F, Lavoie, P, Jacobson, K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Poster of Distinction
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8859343/
http://dx.doi.org/10.1093/jcag/gwab049.044

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8859343/
http://dx.doi.org/10.1093/jcag/gwab049.044

Ejemplares similares